Clario与AWS合作，利用生成式AI突破临床数据分析的新界限-动脉网

Clario Collaborates with AWS to Push New Boundaries in Clinical Data Analysis with Generative AI

CISION 等信源发布 2025-04-16 22:00



可切换为仅中文







Clario's Advanced AI-Powered Platform Streamlines Clinical Document Processing to Facilitate Faster Drug Development Timelines

Clario的先进AI驱动平台简化了临床文档处理，以促进更快的药物开发时间表。

PHILADELPHIA

费城

，

April 16, 2025

2025年4月16日

/PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced a multi-year agreement with Amazon Web Services (AWS) to advance its generative AI platform. By leveraging AWS's AI and machine learning technologies, Clario is enabling healthcare and life sciences organizations to process complex documents and trial data with enhanced speed and accuracy, reducing clinical trial startup times..

/PRNewswire/ -- 全球临床试验行业领先的终点数据解决方案提供商Clario今天宣布与亚马逊云服务（AWS）达成多年协议，以推进其生成式人工智能平台。通过利用AWS的人工智能和机器学习技术，Clario正在帮助医疗保健和生命科学组织更快速、更准确地处理复杂文件和试验数据，从而缩短临床试验的启动时间。

'Our collaboration with AWS represents a pivotal step forward in Clario's mission to streamline operations and deliver regulatory-grade data faster,' said

“我们与AWS的合作代表了Clario在简化运营和更快提供符合监管要求的数据这一使命中迈出了关键一步，”

Jay Ferro

杰·费罗

, Chief Information, Technology and Product Officer at Clario. 'By harnessing the power of AI, we're not only reducing operational burdens, but also improving data accuracy and quality to help our customers achieve greater compliance, and ultimately, improved patient outcomes.'

Clario的首席信息、技术和产品官表示：“通过利用人工智能的力量，我们不仅减少了运营负担，还提高了数据的准确性和质量，以帮助我们的客户实现更高的合规性，并最终改善患者的治疗效果。”

Clario has long been dedicated to investing in AI to support our customers as they adapt to the ever-evolving clinical trial landscape. This collaboration demonstrates an innovative approach that applies AWS capabilities to create a robust multi-modal data analysis pipeline. Clario's proprietary generative AI platform orchestrates multiple large language models and deep learning models using AWS infrastructure to achieve best in class results.

Clario 一直以来都致力于投资人工智能，以支持我们的客户适应不断变化的临床试验环境。此次合作展示了一种创新的方法，利用 AWS 的能力创建了一个强大的多模态数据分析管道。Clario 专有的生成式人工智能平台使用 AWS 的基础设施，协调多个大型语言模型和深度学习模型，以实现业内最佳结果。

This scalable system enables the rapid processing of clinical documents and multi-modal data, transforming vast volumes of unstructured information into actionable insights, empowering life sciences companies to accelerate innovation..

该可扩展系统能够快速处理临床文档和多模态数据，将大量非结构化信息转化为可操作的洞见，助力生命科学公司加速创新。

A vision for scalable innovation

一个可扩展创新的愿景

Working with AWS, Clario is successfully implementing AI in life sciences. By adopting an iterative approach to model development and optimizing each phase of analysis, Clario is delivering a scalable solution tailored to the unique challenges of clinical trials.

通过与AWS合作，Clario成功地在生命科学领域实施了人工智能。通过采用迭代方法进行模型开发并优化分析的每个阶段，Clario提供了一个可扩展的解决方案，专门应对临床试验的独特挑战。

'AI, and specifically generative AI, is a game changer for our industry,' said

“人工智能，特别是生成式人工智能，是我们行业的游戏规则改变者，”

Marko Topalovic

马尔科·托帕洛维奇

, Chief AI Officer at Clario. 'Our commitment to using cutting-edge technology like AWS's comprehensive suite of services, combined with strategic, future focused approach to redefine clinical trial conduct, allows us to experiment, refine, and deploy solutions that meet the evolving needs of our clients while maintaining the highest standards of quality and compliance.'.

Clario首席人工智能官表示：“我们致力于使用像AWS全面的服务套件这样的尖端技术，结合战略性、前瞻性方法重新定义临床试验的执行方式，使我们能够试验、完善并部署满足客户不断变化需求的解决方案，同时保持最高标准的质量和合规性。”

'We're excited to work with Clario to support the advancement of clinical trial data management using generative AI to analyze endpoint data across imaging, cardiac safety, eCOA, and respiratory assessments,' said

“我们很高兴与Clario合作，利用生成式人工智能推动临床试验数据管理的发展，以分析成像、心脏安全、电子临床结果评估（eCOA）和呼吸评估等终点数据，”

Allyson Fryhoff

艾莉森·弗莱霍夫

, Managing Director of Healthcare & Life Sciences at AWS. 'Their work underscores the huge opportunity that advanced technologies bring to drug development by transforming unstructured data into insights that help sponsors get effective therapies to patients faster than ever before.'

AWS医疗保健与生命科学董事总经理。“他们的工作强调了先进技术为药物开发带来的巨大机遇，这些技术通过将非结构化数据转化为洞察力，帮助赞助商以前所未有的速度将有效疗法带给患者。”

To discover more about this collaboration,

要了解更多关于这次合作的信息，

visit this AWS Architecture Blog

访问此 AWS 架构博客

co-authored by Clario's Director of AI,

由Clario的人工智能总监共同撰写，

Alex Boudreau

亚历克斯·布德罗

, and AWS's Principal Solutions Architect,

，以及AWS的首席解决方案架构师，

John O'Donnell

约翰·奥唐纳

。

About Clario

关于Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence generation solutions that combine medical imaging, eCOA, precision motion, cardiac solutions and respiratory endpoints..

Clario是为临床试验行业提供终点数据解决方案的领先供应商，为生命科学公司生成高质量的临床证据。我们提供全面的证据生成解决方案，结合了医学影像、电子临床结果评估（eCOA）、精密运动、心脏解决方案和呼吸终点。

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012..

五十多年来，Clario 一直提供深入的科学专业知识和广泛的终点技术，帮助改变世界各地人们的生活。我们的终点数据解决方案已支持了在一百多个国家进行的超过 26,000 次临床试验。自 2012 年以来，我们全球的科学、技术和运营专家团队已支持了所有 FDA 药品批准中的 60% 以上。

For more information, visit

欲了解更多信息，请访问

Clario.com

or follow on

或者继续关注

领英

。

Media Contact:

媒体联系人:

media@clario.com

媒体@克拉里奥.com